| Interaction Color Code | Clinical Bottom Line | Clinical Effects | Drug 1 effect | Drug 2 dose | Drug 2 effect | Management | |
|---|---|---|---|---|---|---|---|
| Lenacapavir Pitavastatin 1 | Green: Administer standard doses | Administer standard doses | No clinically significant effect expected |
Not reported |
2 mg x 1 (with food), administered 3 days after LEN | AUC decreased 4% |
|
| Lenacapavir Pitavastatin | Green: Administer standard doses | Administer standard doses | No clinically significant effect expected |
Not reported |
2 mg x 1 (with food, simultaneous administration with oral LEN) | AUC increased 11% |
|
| Darunavir Pitavastatin 905 | Green: Administer standard doses | Administer standard doses | No significant change |
4 mg once daily | AUC decreased 26% |
||
| Atazanavir Pitavastatin 765 | Yellow: Adjust dosing | Adjust dosing to avoid increased levels of pitavastatin | Potential for increased pitavastatin adverse effects |
No significant change |
4 mg daily | Pitavastatin AUC increased 31%, Cmax increased 60% |
Start at lowest dose and titrate to effect |
| Elvitegravir Pitavastatin 144 | Yellow: Adjust dosing | Adjust dosing to avoid increased levels of pitavastatin | Potential for increased risk of pitavastatin adverse effects |
Initiate pitavastatin at lowest dose and titrate carefully. Monitor for adverse effects. |
|||
| Fostemsavir Pitavastatin 31 | Orange: Minimal data to guide interaction | Minimal data to guide interaction: weigh risks and benefits of using this combination | Increased statin exposure and risk of statin associated adverse events |
If co-adminstering, use lowest possible starting dose and monitor for statin associated adverse events |
